United Gene High-Tech Group Limited provided consolidated earnings guidance for the nine months ended March 31, 2014. For the period, the Group is expected to record a substantial increase in the consolidated net loss as compared with the twelve months ended June 30, 2013, due to loss on the acquisition of the convertible bonds issued by Extrawell Pharmaceutical Holdings Limited; subsequent fair value change on the convertible bonds issued by Extrawell;loss on the acquisition of investment in associate, Extrawell; and the impairment loss on the investment in associate, Extrawell. This is based on a preliminary review of the unaudited consolidated management accounts of the Group for the nine months ended March 31, 2014.